EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

rFIP‐GMI Suppresses IGF‐1–Induced Invasion and Migration in Breast Cancer Cells via PI3K/Akt/β‐Catenin Inhibition

Wen-Ling Liao, Yu-Ying Wu, Yu-Fan Liu, Pei-Chi Lan, Yu-Chun Cheng, Yueh-Tzu Hung, Hsin-Wen Liang, Huei-Jane Lee iD, Yi-Hsien Hsieh iD, Chun-Wen Cheng iD

Drug Development Research · 2025

DOI: 10.1002/ddr.70202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Wen-Ling Liao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor I, Triple Negative Breast Neoplasms, Breast Neoplasms. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was financially supported by the Grants of China Medical University Taichung, Taiwan (R.O.C) (CMU-112-SR-49 to Wen-Ling Liao) and Chung Shan Medical….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulin‐like growth factor‐1 (IGF‐I) promotes breast cancer (BC) progression by activating the phosphatidylinositol 3‐kinase (PI3K)/Akt pathway, which enhances invasion and migration through β‐catenin–mediated epithelial–mesenchymal transition (EMT). Triple‐negative breast cancer (TNBC), an aggressive BC subtype lacking hormone receptors and HER2 expression, exhibits high metastatic potential, poor prognosis, and limited therapeutic options. The recombinant fungal immunomodulatory protein from Ganoderma microsporum (rFIP‐GMI) possesses anti‐inflammatory, anti‐allergic, and anticancer activities; however, its role in suppressing tumor invasion and migration remains unclear. In this study, we investigated the molecular mechanism of rFIP‐GMI in TNBC cell lines, Hs578T and MDA‐MB‐231. Cell invasion and migration were evaluated using Boyden chamber and Transwell migration assays, while Western blot analysis and nuclear/cytoplasmic fractionation were employed to analyze protein expression and β‐catenin localization. rFIP‐GMI significantly inhibited IGF‐1–induced invasion and migration in both TNBC cell lines. Mechanistically, rFIP‐GMI suppressed PI3K and Akt phosphorylation, thereby activating glycogen synthase kinase‐3 beta (GSK3β) and promoting β‐catenin phosphorylation and degradation. This led to reduced nuclear β‐catenin accumulation and downregulation of oncogenic targets, including c‐Myc, cyclin D1, and MMP‐9. Conversely, treatment with the proteasome inhibitor MG132 confirmed that rFIP‐GMI stabilized cytoplasmic β‐catenin phosphorylation and blocked its nuclear translocation. Collectively, these findings demonstrate that rFIP‐GMI inhibits IGF‐1–driven invasion and migration in TNBC by inactivating the PI3K/Akt/β‐catenin axis, highlighting its potential as a therapeutic agent for this aggressive TNBC subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Like Growth Factor ITriple Negative Breast NeoplasmsBreast NeoplasmsHumansbeta CateninCell MovementProto-Oncogene Proteins c-aktCell Line, TumorFemaleNeoplasm InvasivenessSignal TransductionPhosphatidylinositol 3-KinasesEpithelial-Mesenchymal TransitionRecombinant Proteins

Stichwörter der Autor:innen

EMTIGF‐1PI3K/Akt pathwaybreast cancerrFIP‐GMI

Substanzen

beta CateninProto-Oncogene Proteins c-aktInsulin-Like Growth Factor ICTNNB1 protein, humanPhosphatidylinositol 3-KinasesIGF1 protein, humanRecombinant Proteins

Autor:innen und Institutionen

  • Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
  • Center for Personalized Medicine, China Medical University Hospital, Taichung, Taiwan.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Orthopedics, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Department of Biomedical Sciences, Chung Shan Medical University, Taichung, Taiwan.
  • Division of Digestive Medicine, Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan.

ORCID-Profile: Huei-Jane Lee, Yi-Hsien Hsieh, Chun-Wen Cheng

Förderung

  • This study was financially supported by the Grants of China Medical University Taichung, Taiwan (R.O.C) (CMU-112-SR-49 to Wen-Ling Liao) and Chung Shan Medical…

Zitieren

APA

Liao, W. L., Wu, Y. Y., Liu, Y. F., Lan, P. C., Cheng, Y. C., Hung, Y. T., Liang, H. W., Lee, H. J., Hsieh, Y. H., & Cheng, C. W. (2025). rFIP‐GMI Suppresses IGF‐1–Induced Invasion and Migration in Breast Cancer Cells via PI3K/Akt/β‐Catenin Inhibition. Drug Development Research. https://doi.org/10.1002/ddr.70202

Vancouver

Liao WL, Wu YY, Liu YF, Lan PC, Cheng YC, Hung YT, et al. rFIP‐GMI Suppresses IGF‐1–Induced Invasion and Migration in Breast Cancer Cells via PI3K/Akt/β‐Catenin Inhibition. Drug Development Research. 2025. doi:10.1002/ddr.70202

BibTeX
@article{Liao2025,
  author = {Liao, Wen-Ling and Wu, Yu-Ying and Liu, Yu-Fan and Lan, Pei-Chi and Cheng, Yu-Chun and Hung, Yueh-Tzu and Liang, Hsin-Wen and Lee, Huei-Jane and Hsieh, Yi-Hsien and Cheng, Chun-Wen},
  title = {rFIP‐GMI Suppresses IGF‐1–Induced Invasion and Migration in Breast Cancer Cells via PI3K/Akt/β‐Catenin Inhibition},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70202}
}
Kostenlos starten →